glycyl-glycyl-cysteine has been researched along with gluconic acid in 1 studies
| Studies (glycyl-glycyl-cysteine) | Trials (glycyl-glycyl-cysteine) | Recent Studies (post-2010) (glycyl-glycyl-cysteine) | Studies (gluconic acid) | Trials (gluconic acid) | Recent Studies (post-2010) (gluconic acid) |
|---|---|---|---|---|---|
| 7 | 0 | 2 | 1,164 | 105 | 395 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Altai, M; Honarvar, H; Larsson, E; Löfblom, J; Lubberink, M; Orlova, A; Sandström, M; Ståhl, S; Strand, J; Strand, SE; Tolmachev, V; Varasteh, Z; Wållberg, H | 1 |
1 other study(ies) available for glycyl-glycyl-cysteine and gluconic acid
| Article | Year |
|---|---|
188Re-ZHER2:V2, a promising affibody-based targeting agent against HER2-expressing tumors: preclinical assessment.
Topics: Animals; Antibodies; Cell Line, Tumor; Chelating Agents; Drug Evaluation, Preclinical; Female; Gluconates; Humans; Mice; Mice, Nude; Oligopeptides; Ovarian Neoplasms; Peptides; Radiation Dosage; Radioisotopes; Radiometry; Radiopharmaceuticals; Receptor, ErbB-2; Rhenium; Xenograft Model Antitumor Assays | 2014 |